{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:42:50Z","timestamp":1783986170558,"version":"3.55.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Stevens\u2013Johnson syndrome and toxic epidermal necrolysis (SJS\/TEN) are life-threatening conditions best approached with multidisciplinary burn-equivalent care. There is a lack of consensus on wound management, in particular, whether to debride detached epidermis. Our center instituted \u201cantishear\u201d wound therapy 35 years ago, where detached skin is left in situ as a biologic dressing and a standardized protocol avoids shear forces to prevent further desquamation. Our center\u2019s initial results showed outcomes comparable to SCORTEN predictions, but advancements in burn critical care necessitate a reevaluation of the antishear approach. A retrospective chart review was conducted for all patients admitted between June 2004 and May 2020 with a dermatologist-confirmed diagnosis of SJS\/TEN (N = 51). All patients were treated with burn-equivalent critical care and antishear wound therapy. Standardized mortality ratios were calculated using the established SCORTEN, and newly developed ABCD-10, prediction models. Mean SCORTEN, ABCD-10, and %TBSA were 2.6, 2.0, and 28%. Overall mortality was 22%; SCORTEN score (P &amp;lt; .001), ABCD-10 score (P &amp;lt; .01), %TBSA involved (P = .02), and development of multisystem organ failure (P &amp;lt; .001) correlated with increased mortality. Cohort-wide standardized mortality based on ABCD-10 was 1.18 (P = .79). Standardized mortality based on SCORTEN was 0.62 (P = .20) and 0.77 (P = .15) for patients with scores \u22643 and &amp;gt;3; across the cohort it was 0.71 (P = .11), representing a 29% mortality reduction. Incorporating the antishear approach as part of burn-equivalent care for SJS\/TENs led to outcomes comparable to those predicted for surgical debridement via SCORTEN. However, the antishear approach has the advantage of avoiding painful dressing changes, sedation, and general anesthesia required for surgical debridement.<\/jats:p>","DOI":"10.1093\/jbcr\/irab155","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T20:39:02Z","timestamp":1628541542000},"page":"1152-1161","source":"Crossref","is-referenced-by-count":10,"title":["Antishear Therapy for Stevens\u2013Johnson Syndrome and Toxic Epidermal Necrolysis: A Follow-up Study"],"prefix":"10.1093","volume":"42","author":[{"given":"Pranav N","family":"Haravu","sequence":"first","affiliation":[{"name":"Pritzker School of Medicine, University of Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Section of Plastic & Reconstructive Surgery, University of Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3895-2181","authenticated-orcid":false,"given":"Sebastian Q","family":"Vrouwe","sequence":"additional","affiliation":[{"name":"Section of Plastic & Reconstructive Surgery, University of Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"2021120105064490000_CIT0001","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"2021120105064490000_CIT0002","doi-asserted-by":"crossref","first-page":"173.e1","DOI":"10.1016\/j.jaad.2013.05.003","article-title":"Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2021120105064490000_CIT0003","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis in United States Adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2021120105064490000_CIT0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.anai.2016.11.019","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"118","author":"Eginli","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2021120105064490000_CIT0005","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch Dermatol"},{"key":"2021120105064490000_CIT0006","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/archdischild-2013-303718","article-title":"A review of causes of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in children","volume":"98","author":"Ferrandiz-Pulido","year":"2013","journal-title":"Arch Dis Child"},{"key":"2021120105064490000_CIT0007","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/toxins6010194","article-title":"Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions","volume":"6","author":"Su","year":"2014","journal-title":"Toxins (Basel)"},{"key":"2021120105064490000_CIT0008","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1248\/yakushi.14-00249-3","article-title":"Predictive genomic markers for severe adverse drug reactions","volume":"135","author":"Saito","year":"2015","journal-title":"Yakugaku Zasshi"},{"key":"2021120105064490000_CIT0009","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J. Invest Dermatol"},{"key":"2021120105064490000_CIT0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/TME.0000000000000225","article-title":"A review of the management of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"41","author":"Woolum","year":"2019","journal-title":"Adv Emerg Nurs J"},{"key":"2021120105064490000_CIT0011","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"2021120105064490000_CIT0012","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Gu\u00e9gan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"2021120105064490000_CIT0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2021120105064490000_CIT0014","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjd.14799","article-title":"Major psychological complications and decreased health-related quality of life among survivors of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"175","author":"Dodiuk-Gad","year":"2016","journal-title":"Br J Dermatol"},{"key":"2021120105064490000_CIT0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2340\/00015555-2295","article-title":"Long-term sequelae of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"96","author":"Yang","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"2021120105064490000_CIT0016","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis-ABCD-10","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2021120105064490000_CIT0017","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"2021120105064490000_CIT0018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2021120105064490000_CIT0019","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/2042098611404094","article-title":"Systematic review of treatments for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality","volume":"2","author":"Roujeau","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"2021120105064490000_CIT0020","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.burns.2015.12.001","article-title":"Burn unit care of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: a survey","volume":"42","author":"Le","year":"2016","journal-title":"Burns"},{"key":"2021120105064490000_CIT0021","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s12325-017-0530-y","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures","volume":"34","author":"Schneider","year":"2017","journal-title":"Adv Ther"},{"key":"2021120105064490000_CIT0022","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021120105064490000_CIT0023","doi-asserted-by":"crossref","first-page":"e12758","DOI":"10.1111\/dth.12758","article-title":"Efficacy and safety of cyclosporine in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"32","author":"Gilbert","year":"2019","journal-title":"Dermatol Ther"},{"key":"2021120105064490000_CIT0024","first-page":"6274053","article-title":"IVIG and under burn unit care yield favorable outcomes in pediatric patients with toxic epidermal necrolysis: a case report and literature review","volume":"2020","author":"Alzughayyar","year":"2020","journal-title":"Case Rep Dermatol Med"},{"key":"2021120105064490000_CIT0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00000637-198802000-00011","article-title":"Survival after a second episode of toxic epidermal necrolysis","volume":"20","author":"Dreyfuss","year":"1988","journal-title":"Ann Plast Surg"},{"key":"2021120105064490000_CIT0026","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PRS.0b013e3181773d5d","article-title":"Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach","volume":"122","author":"Dorafshar","year":"2008","journal-title":"Plast Reconstr Surg"},{"key":"2021120105064490000_CIT0027","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bjps.2014.04.003","article-title":"Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm","volume":"67","author":"Abela","year":"2014","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2021120105064490000_CIT0028","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"2021120105064490000_CIT0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13023-018-0793-7","article-title":"Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins)","volume":"13","author":"Ingen-Housz-Oro","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2021120105064490000_CIT0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"2021120105064490000_CIT0031","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"2021120105064490000_CIT0032","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamadermatol.2020.3654","article-title":"Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis","volume":"156","author":"Koh","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2021120105064490000_CIT0033","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/1346-8138.15490","article-title":"Accuracy of SCORTEN and ABCD-10 to predict mortality and the influence of renal function in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"47","author":"Torres-Navarro","year":"2020","journal-title":"J. Dermatol"},{"key":"2021120105064490000_CIT0034","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and Steven\u2013Johnson syndrome: a comprehensive review","volume":"9","author":"Charlton","year":"2020","journal-title":"Adv Wound Care"},{"key":"2021120105064490000_CIT0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"2021120105064490000_CIT0036","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/01.PRS.0000019761.69444.10","article-title":"Outcome of patients with toxic epidermal necrolysis syndrome revisited","volume":"110","author":"Ducic","year":"2002","journal-title":"Plast Reconstr Surg"},{"key":"2021120105064490000_CIT0037","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients\u2014treatment and outcome","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergol Int"},{"key":"2021120105064490000_CIT0038","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.amjsurg.2015.12.011","article-title":"Indications for intubation and early tracheostomy in patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"211","author":"Williams","year":"2016","journal-title":"Am J Surg"},{"key":"2021120105064490000_CIT0039","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jaad.2019.05.096","article-title":"Risk factors and diagnostic markers of bacteremia in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a cohort study of 176 patients","volume":"81","author":"Koh","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2021120105064490000_CIT0040","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.jaad.2018.05.1258","article-title":"Wound management strategies in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: an unmet need","volume":"79","author":"Lee","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/irab155\/39847960\/irab155.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/42\/6\/1152\/41281302\/irab155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/42\/6\/1152\/41281302\/irab155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T06:54:27Z","timestamp":1638341667000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/42\/6\/1152\/6346786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,8,9]]},"published-print":{"date-parts":[[2021,11,24]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/irab155","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,8,9]]}}}